Antibody-Drug Conjugate– tag –
-
C4 Therapeutics Enters New Partnership with Roche for Degrader-Antibody Conjugate (DAC) Development, Reports Strong Q2
C4 Therapeutics, Inc. USA Overview C4 Therapeutics (C4T) reported robust financial results for Q2 2026 and announced a new collaboration agreement with Roche to advance research into degrader-antibody conjugate (DAC) modalities. This str... -
AsymBio Secures $184 Million in Funding to Expand Biologics CDMO Operations, Boosting ADC and Bispecific Antibody Manufacturing Capacity
Pharma Manufacturing China Overview Shanghai-based biologics CDMO AsymBio has successfully raised approximately $184 million (RMB 1.24 billion) in new funding to significantly expand its biologics development and manufacturing operations... -
Daiichi Sankyo’s DXd ADC Pipeline Advances: ENHERTU Files for HER2-Low/Ultra-Low Breast Cancer, Dato-DXd Gains FDA Breakthrough Therapy for EGFRm NSCLC
Quartr Japan Overview Daiichi Sankyo reported significant progress in its DXd antibody-drug conjugate (ADC) pipeline, with ENHERTU showing efficacy in HER2-low and ultra-low breast cancer, leading to global regulatory submissions. Datopo... -
Pathos AI Licenses Alphamab’s First-in-Class TROP2/HER3 Bispecific ADC JSKN016 in $2.25 Billion Deal to Advance Breast Cancer Treatment
Fierce Biotech USA Overview Pathos AI has licensed JSKN016, a first-in-class TROP2/HER3 bispecific antibody-drug conjugate (ADC) from Alphamab, in a deal worth up to $2.25 billion ($125 million upfront, $2.1 billion in milestones). JSKN0... -
Asia-Pacific AI Drug Discovery Platforms Mature, Achieving Key Clinical Milestones
BioPharma APAC Asia-Pacific Overview AI drug discovery platforms in the Asia-Pacific region are demonstrating significant clinical traction, with Hummingbird Bioscience initiating patient dosing for its HER3-targeted ADC and Insilico Med... -
Revolutionizing TNBC Treatment: Datroway ADC Gains EU Nod for Immunotherapy-Ineligible Patients
Precision Medicine Online European Union Overview AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate (ADC), Datroway (datopotamab deruxtecan), has received European Commission approval as a first-line monotherapy for patients with ... -
Asia-Pacific Revolutionizes Pharma Manufacturing: Surging Capabilities in HPAPIs, Biologics, and Advanced Therapies
BioProcess International Asia-Pacific Overview The Asia-Pacific (APAC) region is rapidly expanding its specialized pharmaceutical manufacturing capabilities beyond traditional APIs, focusing on high-value modalities like HPAPIs, ADCs, mR... -
China’s AsymBio Secures $184M to Dramatically Expand Biologics CDMO Capacity, Bolstering ADC Production
PharmaSource China Overview AsymBio, a Chinese biologics CDMO, secured approximately $184 million (1.2397 billion Yuan) in financing to substantially expand its manufacturing capacity, R&D capabilities, GMP manufacturing lines, and h... -
CDMOs Boost Sterile Fill-Finish and Prefilled Syringe Capacity by Over $1 Billion to Meet Biologics and GLP-1 Drug Demand
BioProcess International USA Overview Contract Manufacturing and Development Organizations (CMOs/CDMOs) are making multi-billion dollar investments, including PCI Pharma Services' global $1 billion expansion, to significantly increase st... -
Fujifilm Prepares for Patent Cliff with Strategic CDMO Investments; Samsung Biologics Acquires PolyPeptide for $1.8B, Entering Peptide Market
Endpoints News Global Overview The pharmaceutical industry faces a 'patent cliff' with ~$300 billion in branded drug revenues at risk from 2025-2030, driving active deals for portfolio expansion and cost efficiency. Contract Development ...
